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The ePidemiology of medical TreaTmenT for glaucoma and ocular 
hyPerTenSion in germany
Ernst F.
Santen GmbH, Munich, Germany
Objectives: The purpose of this study is to review the epidemiology and the treat-
ment paradigm of German glaucoma population and to assess the frequency of 
switches from monotherapy to second- or third line combination therapy in primary 
open angle glaucoma (POAG) patients. Glaucoma is the second leading cause of 
blindness globally. The newly published EGS guidelines state that if the first choice 
monotherapy is well tolerated and has effective intra ocular pressure (IOP) lowering 
but has not succeeded in reaching the target pressure, the addition of a second drug 
should be considered. MethOds: German patient databases were searched in the 
following areas: glaucoma prevalence and incidence studies in German popula-
tion as well as treatment paradigm in glaucoma patients. Results: Our analysis 
underlines the high number of glaucoma patients in Germany and the relevance of 
this disease for the German health care system. The study also demonstrates that 
a considerable number of glaucoma patients do not reach IOP target under mono-
therapy and have to be treated with a combination therapy. In general, treatment 
with a combination of agents of different classes is associated with superior IOP 
lowering efficacy. With an increasing number of available fixed dose combination 
products, more options become available for combination therapy of glaucoma 
patients. cOnclusiOns: Glaucoma care needs to be given high priority in public 
health programs. Especially treatment options for glaucoma patients in need for a 
combination therapy should be in the focus of health care system decision makers 
as well as further research in glaucoma clinical trials and clinical care.
SenSory SySTemS diSorderS – cost Studies
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a uS hoSPiTal economic imPacT model for oriTavancin in abSSSi 
PaTienTS WiTh riSk of mrSa infecTionS
Wu C.1, Fortier K.J.1, LaPensee K.2, Fan W.2, Mitchell M.2, Cyr P.L.1, Jensen I.S.1
1ICON plc, Cambridge, MA, USA, 2The Medicines Company, Parsippany, NJ, USA
Objectives: It is estimated that acute bacterial skin and skin structure infections 
(ABSSSI) account for about 10% of hospital admissions in the US. Analyses of hos-
pital claims indicate 74% of ABSSSI admissions involve empiric treatment with 
methicillin-resistant Staphylococcus aureus (MRSA) active antibiotics. Hospitalization 
costs could be reduced if moderate-severe ABSSSI patients were treated to a greater 
extent in the observational unit followed by discharge to outpatient parenteral 
antibiotic therapy (OPAT). Oritavancin is a novel single-dose regimen, intrave-
nous lipoglycopeptide antibiotic for ABSSSIs caused by gram-positive bacteria, 
including MRSA. The aim of our analysis was to quantify the economic value of 
using oritavancin for ABSSSI patients at risk of MRSA from a US hospital perspec-
tive. MethOds: A decision analytic model based on current clinical practice was 
developed to estimate the economic value of decreased hospital resources by using 
oritavancin. Utilization of antibiotics was informed by analysis of the Premier hos-
pital database. Demographic and clinical data were derived from a targeted litera-
ture review. ER, observation, laboratory, administration costs were from Medicare 
National Limitation amounts. Drug costs were 2014 wholesale acquisition costs. To 
estimate the economic impact of reducing resources using oritavancin we set its 
price to $0. Results: For a hypothetical US hospital treating 1,000 ABSSSI patients 
eligible for IV MRSA antibiotics/year, the administration of oritavancin in 25.75% of 
patients facilitates shifting patients to the OPAT setting (441 to 561 patients) with 
a total annual economic impact of $2,752K. Inpatient and outpatient costs were 
reduced by $2,543K and $209K, respectively. Inpatient cost savings were derived from 
a reduction in hospitalizations and lower administration burden drove decreased 
OPAT costs. cOnclusiOns: Using oritavancin in moderate-severe ABSSSI patients, 
including those at risk of MRSA, is estimated to deliver an estimated cost reduc-
tion of $2,752/patient by shifting patient care to the OPAT setting, and decreasing 
resource utilization.
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economic imPacT of viSual imPairmenT: a PiloT STudy in SingaPore
Wang X.1, Luo N.2, Lamoureux E.3, Ang M.4
1National University of Singapore, Singapore, 2Saw Swee Hock School of Public Health, National 
University of Singapore, Singapore, 3University of Melbourne, Melbourne, Australia,, 4Singapore 
National Eye Center, Singapore
Objectives: To examine the economic impact and independent determinants of 
visual impairment (VI) in Singapore. MethOds: 100 patients with VI associated 
with the most common eye diseases were recruited from the Singapore National Eye 
Centre. VI was classified as mild and moderate/severe VI based on the presenting 
visual acuity (VA) in the better-seeing eye. Medical costs (MC) and loss of productiv-
ity (LP) in the patients and their families were estimated based on the center’s billing 
data and self-reported data, respectively. LP was calculated for working patients 
based on absenteeism due to VI. Linear regression models were used to assess the 
association between costs and VI, generic (EQ-5D), and vision-specific quality of 
life (VF-14). Results: The median (range) age of participants was 73.0 years old 
(47.0-92.0). The proportion of male was 48.0% and the median (range) presenting 
VA was 0.54 (0.30-2.00). The yearly median (range) MC and LP were S$1.53K (S$0.13-
S$83.59K) and S$0 (S$0-S$7.62K) per person, respectively. The yearly MC for those 
with mild VI (S$3.50K) was significantly lower than those with moderate/severe VI 
(S$5.21K) (P< 0.0001). The yearly MC in participants reporting full health or better 
vision function were lower than those not in full health or better vision function 
(e. g. MC for participants in full health= S$2.96K; MC for participants not in full 
health= S$5.19K; P< 0.0001). After adjusting for socio-demographic characteristics, 
the association between MC and VI, EQ-5D and VF-14 remained the same. LP had a 
similar association with EQ-5D and VF-14 with or without adjustment; however, LP 
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clinical effecTiveneSS of fumaric acid eSTerS (fumaderm) in 
PSoriaSiS: a SySTemaTic revieW of liTeraTure
Ceglowska U., Wlodarczyk A., Slomka M.
Agency for Health Technology Assessment In Poland (AHTAPol), Warsaw, Poland
Objectives: To review the literature evaluating the clinical efficacy of Fumaderm 
(FAE) in patients suffering from psoriasis and psoriatic arthritis. MethOds: 
Systematic literature search in electronic databases (MEDLINE, Cochrane and 
Embase) was performed (from inception to March 14,2014). Results were presented 
by narrative synthesis including a quality assessment using Jadad scale. Results: 
Three randomized controlled trials were included (Fallah Arani 2011, Altmeyer 1994, 
Peeters 1992). Quality of studies ranged from 3 to 4 points. Observation period 
was 16 weeks for all studies. One open-label study comparing FAE with metho-
trexate (MTX) in moderate to severe chronic plaque psoriasis was identified. The 
primary efficacy endpoint was the difference in mean change from baseline in 
Psoriasis Area and Severity Index (PASI). After 12 weeks of treatment the mean 
PASI (± SD) decreased to 10.5 ± 6.7 compared with starting value of 18.1 ± 7.0 in 
patients treated with FAE and to 6.7 ± 4.5 compared to starting value of 14.5 ± 
3.0 in patients treated with MTX. The absolute difference between groups (FAE 
vs. MTX) in the mean values was 1.4 (95%CI: 2.0; 4.7) and wasn’t statistically sig-
nificant (p = 0.417). In the remaining two double-blind studies the efficacy and 
safety of Fumaderm was assessed against the placebo. One study shows that in 
psoriasis vulgaris population the mean PASI in FAE group decreased from 21.53 at 
baseline to 10.77, whereas in placebo group mean PASI has not changed (p< 0.0001) 
after 16 weeks of treatment. Moreover, the results of study in psoriatic arthritis 
population revealed that FAE significantly (p< 0.04) decrease joint pain compared 
to placebo. cOnclusiOns: The results revealed that FAE and MTX have similar 
clinical efficacy in the treatment of patients with moderate to severe psoriasis. 
Moreover, FAE is more effective than placebo in the treatment of psoriasis vulgaris 
and psoriatic arthritis.
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knoWledge and PercePTion of medical and Pharmacy STudenTS 
ToWard The uSage of Sunblock
Hadi H., Elkalmi R., Awadh A., Jamshed S., Al-Shami A.
International Islamic University Malaysia, Kuantan, Malaysia
Objectives: To evaluate the knowledge and perception of medical and phar-
macy students toward the usage of sunblock as skin protection against ultraviolet 
(UV). MethOds: This cross-sectional study was conducted among the undergradu-
ate final year medical and pharmacy students at the International Islamic University 
Malaysia (IIUM). Validated questionnaire were used to collect the data. The question-
naires were distributed to 134 students from medicine and 100 pharmacy students. 
Descriptive and inferential statistics are used whenever appropriate. Results: 
Overall, 161 participants out of a total of 234 completed the questionnaire with 
101 medical students (75.4%) and 60 pharmacy students (60.0%). Majority of the 
respondents were female 64 (63.4%) and 37 (36.6%) were male. The median of knowl-
edge scores of the final year medical students was significantly lower than the 
final year pharmacy students (p< 0.01). There is no significant differnce between 
the knowledge of the female and male students (Mann Whitney U Test value = 
0.27, p< 0.01). This study reported that 24 (39.3 %) of pharmacy students were influ-
enced by the media to use sunblock whereas 35 (34.7%) of medical students had the 
highest influence from friends to use sunblock. However, this study showed there 
was no significant difference in the perception of pharmacy and medical studnets 
p= 0.020. cOnclusiOns: In conclusion, the knowledge of pharmacy students is 
significantly higher than the knowledge of medical students had on the usage of 
sunblock. Both medical and pharmacy students have the same level of perception 
towards the usage of sunblock.
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PharmacoePidemiology of cellular/TiSSue derived ProducTS for The 
TreaTmenT of venouS leg ulcerS in ouTPaTienT care SeTTingS
Gilligan A.M., Waycaster C.
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA
Objectives: Venous leg ulcers (VLUs) are a debilitating condition for patients with 
venous insufficiency. Compression therapy is the standard care for treatment of 
VLU; however the success rate is approximately 50% at 6 months. Clinical trials 
with cellular/tissue derived products (CTPs) have shown promising efficacy for 
the treatment of VLU. The objective was to identify patient and clinical character-
istics in the VLU population and examine patterns of CTP utilization. MethOds: 
Retrospective, de-identified electronic medical records from 2007-2013 were 
extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records 
from 96 hospital-based outpatient wound centers. Patient, wound and encounter 
level characteristics were examined. CTPs of interest included extracellular matrix 
(ECM), human skin equivalent (HSE), and living skin equivalent (LSE). Results: 
A total of 9,091 patients, 25,734 wounds, and 222,666 encounters for VLU were 
identified. The majority of patients was male (50.5%), Caucasian (74.1%), and 
reported Medicare as their primary insurance (53.4%). The average age was 68.9 
(SD= 14.6) and the average number of physician visits was 17.7 (SD= 22.5). The mean 
wound surface area was 20.1cm2 (SD= 83.4). The overall average wound duration 
was 5.8 months (SD= 26.7). Of the 25,734 wounds, approximately 7.1% received 
ECM (3.4%), HSE (3.5%), or LSE (0.2%). The average number of applications for ECM 
was 2.7 (SD= 2.8), 0.6 (SD= 1.3) for HSE, and 3.1 (SD= 3.3) for LSE. Wounds treated 
with CTPs were, on average, several months older: 12.5, 13.7, and 11.1 months for 
ECM, HSE, and LSE, respectively. Overall average wound treatment time was 2.9 
months (SD= 4.8). However, treatment time was substantially longer with CTP 
utilization with an average time of 9.6, 9.7, and 7.5 months for ECM, HSE, and LSE, 
respectively. cOnclusiOns: CTP utilization was relatively low within outpatient 
wound centers. Results from this analysis indicate that health care providers are 
using CTPs on older, more difficult-to-heal VLUs.
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coST-analySiS of chronic idioPaThic urTicaria diSeaSe
Tatar M.1, Senturk A.2, Ergin G.2, Tuna E.2, Mat C.3, Bulbul Baskan E.4, Artuz F.5, Gurer M.A.6, 
Atakan N.7, Inaloz S.8, Sezen S.9, Keskinaslan A.9, Saylan M.9
1Hacettepe University, Ankara, Turkey, 2Polar Polar Health Economics & Policy, Ankara, Turkey, 
3Cerrahpasa Medical Faculty, Istanbul, Turkey, 4Uludag Medical Faculty, Bursa, Turkey, 5Ankara 
Numune research and Training Hosptial, Ankara, Turkey, 6Gazi University Medical Faculty, 
Ankara, Turkey, 7Hacettepe University Faculty of Medicine, Ankara, Turkey, 8Gaziantep University 
Medical Faculty, Gaziantep, Turkey, 9Novartis Pharma, Istanbul, Turkey
Objectives: Chronic idiopathic (or spontaneous) urticaria (CIU) is estimated to 
occur in 0.3% of the general population in Turkey. Although the burden of the dis-
ease is substantial for the payer, there has been no cost-analysis performed in our 
country. The purposes of this study are to determine the resources and costs related 
to the diagnosis and treatment of patients with CIU, and to estimate the annual eco-
nomic burden to the Social Security Institution (SGK). MethOds: Delphi technique 
was applied to determine the type and the amount of resources used in different 
stages of CIU defined as mild or moderate to severe based on physicians clinical 
assessment. The Delphi method solicits the opinion of an expert panel through a 
carefully designed questionnaire which in this case included questions on: epi-
demiology, diagnosis, treatment of symptoms and angioedema, adverse events, 
follow-up visits, hospital and emergency service admissions. The responses were 
analysed and discussed in a face to face meeting followed by consensus building 
steps. Unit of resources used for different CIU severity levels were determined from 
expert opinion. Unit costs of resources used in outpatient clinics were obtained 
from SGK’s Reimbursement Guideline-List of Procedure Fees Per Service. Results: 
Hospitalizations, emergency admissions, outpatient visits and treatments, are the 
key cost drivers in the management of CIU The annual cost per patient is calcu-
lated to be 725.36 Turkish Liras (TL) for mild CIU, 1.322,61 TL for moderate CIU and 
2,478.75 TL for severe CIU. The total annual cost of CIU to SGK is estimated to be 262 
million TL in 2014. cOnclusiOns: This is the first study that aims to estimate the 
resource utilisation and cost burden of CIU in Turkey by using the Delphi technique. 
Cost effective treatment of CIU is an unmet need given the heavy burden to SGK 
identified by the Delphi Panel.
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The direcT and indirecT coSTS of WeT age-relaTed macular 
degeneraTion (Wamd) and diabeTic macular edema (dme) in greece
Geitona M.1, Karagiannis D.2, Pantelopoulou G.3, Hatzikou M.3, Kousoulakou H.1
1University of Peloponnese, Corinth, Greece, 2Eye Hospital of Athens, Athens, Greece, 3Novartis 
Hellas, Metamorfosis, Greece
Objectives: Treatment delays in patients with wAMD and DME are very impor-
tant since they are associated with disease progression. This is the first study in 
Greece to highlight patient’s access delays’ to treatment and to estimate the burden 
of diseases in Greece. MethOds: An expert panel with 11 ophthalmologists was 
convened. The experts came from six out of seven Regional Health Authorities, 
covering geographically the largest part of the country. A 13-page questionnaire 
was developed and validated. The Delphi technique was used to collect data on 
resource use and disease management, patient access delays, and indirect costs. 
Unit costs were retrieved from NHS sources and the analysis was conducted from 
the societal perspective, including direct costs incurred by patients, their families 
and the health care system, and indirect costs, of productivity losses. Results: 
Total cost of managing wAMD during the first year of treatment was estimated at 
€ 20,660,32.8% of which consisted of direct costs (drug acquisition and administra-
tion, follow-up, lab and imaging tests), and 67.2% of which included non-medical 
and indirect costs (caregivers). Direct medical cost per DME patient for the first year 
of treatment was estimated at € 6,066, while the non-medical and indirect costs were 
estimated at € 12,271, resulting in a total cost of € 18,337 per patient per year. 91% of 
the experts agreed that there are significant delays in patient access to specific treat-
ments (average 20 days); all agreed (100%) that these delays lead to faster disease 
progression, and a strong majority (> 80%) supported that they lead to deterioration 
of patients’ QoL. cOnclusiOns: There are significant costs associated with the 
management of wAMD and DME in Greece, 70% of which is incurred by patients and 
their families. Administrative procedures leading to patient access delays should be 
minimized in order to avoid disease progression and associated costs.
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economic burden of burn injurieS in The neTherlandS
Hop J.M.1, Wijnen B.F.M.2, Nieuwenhuis M.3, Dokter J.1, Middelkoop E.4, Polinder S.5, van Baar 
M.E.1
1Association of Dutch Burn Centres, Rotterdam, The Netherlands, 2Maastricht University, 
Maastricht, The Netherlands, 3Association of Dutch Burn Centres, Groningen, The Netherlands, 
4Association of Dutch Burn Centres, Beverwijk, The Netherlands, 5Erasmus MC, Rotterdam, The 
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Objectives: Burn care has rapidly improved in the past decades. However, health 
care innovations can be expensive, demanding careful choices on their implementa-
tion. Obtaining knowledge on the extent of the costs of burn injuries is an essential 
first step for economic evaluations within burn care. The objective of this study was 
to determine the economic burden of patients with burns admitted to a burn center 
and to identify important cost categories until three months post-burn. MethOds: 
A prospective cohort study was conducted in the burn center of Maasstad Hospital 
Rotterdam, the Netherlands, including all patients with acute burn related injuries 
from August 2012 until July 2013. Total costs were calculated from a societal perspec-
tive, until three months post injury. Subgroup analyses were performed to examine 
whether the mean total costs per patient differed by age, etiology or percentage 
total body surface area (TBSA) burned. Results: In our population, with a mean 
burn size of 8%, mean total costs were € 24,246 per patient varying from € 11,498 to 
€ 71,756. Most important cost categories were burn center days, surgical interven-
tions and work absence. Flame burns were significantly more costly than other types 
of burns, adult patients were significantly more costly than children and adolescents 
decreased with VI severity (the adjusted difference in LP between participants with 
mild and moderate/severe VI= S$0.22K, P= 0.3846). cOnclusiOns: Visual impair-
ment poses substantial economic burden on individuals and families in Singapore. 
The economic burden of VI is mainly medical costs. Self-reported health problems 
seem to be better predictors of costs of VI than clinical measures.
PSS13
coSTS of burn care: a SySTemaTic revieW
Hop M.J.1, Polinder S.2, Middelkoop E.3, van Baar M.E.1
1Association of Dutch Burn Centres, Rotterdam, The Netherlands, 2Erasmus MC, Rotterdam, The 
Netherlands, 3Association of Dutch Burn Centres, Beverwijk, The Netherlands
Objectives: Burn care is traditionally considered expensive care. However, detailed 
information about the costs of burn care is scarce, despite the increased need for this 
information and the enhanced focus on health care cost control. In this study, eco-
nomic literature on burn care was systematically reviewed to examine the problem 
of burn-related costs. MethOds: Cost or economic evaluation studies on burn care 
that had been published in international peer-reviewed journals from 1950-2012 
were identified. The methodology of these articles was critically appraised by two 
reviewers, and cost results were extracted. Results: A total of 156 studies met the 
inclusion criteria. Nearly all of the studies were cost studies (n= 153) with a health 
care perspective (n= 139) from high income countries (n= 127). Hospital charges were 
often used as a proxy for costs (n= 44). Three studies were cost-effectiveness analy-
ses. The mean total health care cost per burn patient in high-income countries was 
$88,218 (range $704- $717,306, median $44,024). cOnclusiOns: A wide variety of 
methodological approaches and cost prices was found. We recommend that cost 
studies and economic evaluations employ a standard approach to improve the 
quality and harmonization of economic evaluation studies, optimize comparability 
and improve insight into burn care costs and efficiency.
PSS14
coSTS of PSoriaSiS in euroPe. a SySTemaTic revieW of The liTeraTure
Obradors M.1, Figueras M.1, Paz S.2, Comellas M.3, Lizán L.3
1Novartis Farmaceutica S. A., Barcelona, Spain, 2Outcomes’10, Castellon, Spain, 3Outcomes 10, 
Castellon, Spain
Objectives: To appraise the literature referred to direct and indirect costs of pso-
riasis in Europe. MethOds: A systematic review of the literature was performed. 
Electronic databases [MedLine/PubMed, Scopus, Cochrane Library, ISI Wok, MEDES, 
IBECS, CSIC] and Google Scholar were searched to identify publications referred 
to direct and indirect costs of psoriasis in Europe. Bibliographic references were 
hand searched. European studies published in English or Spanish until October 
2013 were selected. Economic evaluations of specific drugs and of preventive or 
diagnostic interventions were excluded. Costs were updated to € , 2013. Results: 
12 studies were reviewed (4 German, 2 Swedish, 2 Italian, 1 Dutch, 1 
French, 1 English and 1 Spanish). From the social perspective, the mean 
annual cost of psoriasis in Europe was heterogeneous and varied between 
€ 1,340.25 (Spain) and € 8,253.74 (Italy), mainly due to differences of study 
sample characteristics, methodology used and national health system 
features. The highest proportion (68%-82.5%) of total costs was attribut-
able to direct costs (hospitalizations, medications and laboratory tests). 
The annual total cost of severe psoriasis was, at least, 2.5 fold superior to the costs 
of mild disease, mostly because of a more frequent use of hospital resources and 
loss of productivity. Out-of-pocket expenditure ranged from € 480.67 to € 797.00, 
being mostly explained by the use of dermatological products (OTC) (29%-59.7%) 
and alternative therapies (balnerotherapies) (24%-49%). The initiation of biologic 
therapies implied reductions of up to 76% on the length of hospital stay and up to 
98% hospital admissions, contributing to a decline of inpatient cost [€ 2,357.30 (SD: 
722.29) vs. € 564.19 (SD: 257.62); p= 0.005; UK]. cOnclusiOns: Costs results vary 
across European countries. Severe psoriasis is a costly disease. The use of biologic 
agents may contribute to a more efficient management of severe psoriasis due to 
a more steady control of symptoms that improve clinical outcomes and decrease 
the needs for hospital care and inpatient cost.
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economic burden of eye diSeaSe in diabeTic PaTienTS: liTeraTure 
revieW
Riera M.1, Granell M.2, Sarycheva A.2, Roura M.2
1Independent Consultant, Molina de Segura, Spain, 2Novartis Farmaceutica, Barcelona, Spain
Objectives: To provide a literature overview on the costs of diabetic complications 
focused on the economic burden of Diabetic Macular Edema (DME) and associated 
vision loss and blindness. MethOds: Literature searches in PubMed (including 
Medline) and Embase were conducted to identify economic data related to diabetic 
retinopathy, macular edema, blindness and low vision. Posterior filters included 
year of publication (from 2000 to May 2014), country (Canada, USA or Europe) and 
English language. Relevant full text articles were reviewed and major findings sum-
marized. Results: A total of 468 citations from 5 different searches were retrieved 
and 16 studies fulfilled the criteria to be summarized in this review. Microvascular 
diabetic complications were found to be frequent and led to a 70% increase in 
direct costs compared to patients with no complications. When microvascular and 
macrovascular complications were given together, management costs increased 
by up to 250%. Eye disease was associated with a 2,5 ratio of extra cost compared 
to diabetic patients without complications, with DME incurring in twice to 3 times 
higher costs related to Diabetic Retinopathy. Direct costs of DME accounted for 
65-80% of total costs, with 73% of those being associated to hospital expenditure. 
Data on the economic burden of visual impairment and blindness were limited: 
vision loss had an annual per capita financial cost of $19.370 in Canada (2007); 
including the value of lost wellbeing, the annual cost of vision loss was $33.704 
per patient. cOnclusiOns: DME appears to be a costly complication of diabetes. 
Progression to visual impairment and blindness can lead to high economic and 
social burden.
